171 related articles for article (PubMed ID: 25099918)
1. A brief literature and patent review of nanosuspensions to a final drug product.
Chin WW; Parmentier J; Widzinski M; Tan EH; Gokhale R
J Pharm Sci; 2014 Oct; 103(10):2980-99. PubMed ID: 25099918
[TBL] [Abstract][Full Text] [Related]
2. Nanosuspension Technology For Poorly Soluble Drugs: Recent Researches, Advances and Patents.
Agarwal V; Bajpai M
Recent Pat Nanotechnol; 2015; 9(3):178-94. PubMed ID: 27009133
[TBL] [Abstract][Full Text] [Related]
3. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects.
Chavhan SS; Petkar KC; Sawant KK
Crit Rev Ther Drug Carrier Syst; 2011; 28(5):447-88. PubMed ID: 22077201
[TBL] [Abstract][Full Text] [Related]
4. Downstream drug product processing of itraconazole nanosuspension: Factors influencing drug particle size and dissolution from nanosuspension-layered beads.
Parmentier J; Tan EH; Low A; Möschwitzer JP
Int J Pharm; 2017 May; 524(1-2):443-453. PubMed ID: 28400290
[TBL] [Abstract][Full Text] [Related]
5. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies.
Zhang X; Li LC; Mao S
Curr Pharm Des; 2014; 20(3):388-407. PubMed ID: 23651400
[TBL] [Abstract][Full Text] [Related]
6. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
[TBL] [Abstract][Full Text] [Related]
7. Study on formability of solid nanosuspensions during nanodispersion and solidification: I. Novel role of stabilizer/drug property.
Yue PF; Li Y; Wan J; Yang M; Zhu WF; Wang CH
Int J Pharm; 2013 Sep; 454(1):269-77. PubMed ID: 23830942
[TBL] [Abstract][Full Text] [Related]
8. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
Pardeike J; Strohmeier DM; Schrödl N; Voura C; Gruber M; Khinast JG; Zimmer A
Int J Pharm; 2011 Nov; 420(1):93-100. PubMed ID: 21889582
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
Kocbek P; Baumgartner S; Kristl J
Int J Pharm; 2006 Apr; 312(1-2):179-86. PubMed ID: 16469459
[TBL] [Abstract][Full Text] [Related]
11. Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs.
Wang Y; Miao X; Sun L; Song J; Bi C; Yang X; Zheng Y
Curr Pharm Des; 2014; 20(3):454-73. PubMed ID: 23651402
[TBL] [Abstract][Full Text] [Related]
12. Freeze drying of nanosuspensions, 2: the role of the critical formulation temperature on stability of drug nanosuspensions and its practical implication on process design.
Beirowski J; Inghelbrecht S; Arien A; Gieseler H
J Pharm Sci; 2011 Oct; 100(10):4471-81. PubMed ID: 21607957
[TBL] [Abstract][Full Text] [Related]
13. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
Mou D; Chen H; Wan J; Xu H; Yang X
Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
[TBL] [Abstract][Full Text] [Related]
14. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
[TBL] [Abstract][Full Text] [Related]
15. Dual centrifugation - A new technique for nanomilling of poorly soluble drugs and formulation screening by an DoE-approach.
Hagedorn M; Bögershausen A; Rischer M; Schubert R; Massing U
Int J Pharm; 2017 Sep; 530(1-2):79-88. PubMed ID: 28733242
[TBL] [Abstract][Full Text] [Related]
16. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products.
Van Eerdenbrugh B; Van den Mooter G; Augustijns P
Int J Pharm; 2008 Nov; 364(1):64-75. PubMed ID: 18721869
[TBL] [Abstract][Full Text] [Related]
17. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions.
Kayaert P; Li B; Jimidar I; Rombaut P; Ahssini F; Van den Mooter G
Eur J Pharm Biopharm; 2010 Nov; 76(3):507-13. PubMed ID: 20887787
[TBL] [Abstract][Full Text] [Related]
18. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets.
Salazar J; Müller RH; Möschwitzer JP
Eur J Pharm Sci; 2013 Jul; 49(4):565-77. PubMed ID: 23587645
[TBL] [Abstract][Full Text] [Related]
19. Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement.
Taneja S; Shilpi S; Khatri K
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):978-84. PubMed ID: 25724312
[TBL] [Abstract][Full Text] [Related]
20. Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies.
Du J; Li X; Zhao H; Zhou Y; Wang L; Tian S; Wang Y
Int J Pharm; 2015 Nov; 495(2):738-49. PubMed ID: 26383838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
